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1INTRODUCTION
Hepatitis B virus occurs worldwide and constitutes a serious public
problem. According to WHO, HBV infection is 100 times more lethal than
HIV and therefore requires more  attention. Despite availability of a vaccine,
HBV infection is endemic, estimated to affect  400million people worldwide
with very high carriage rate (up to 20%) particularly in south and  East Asia.
Worldwide vertical transmission remains the most frequent route of infection
particularly in endemic areas where up to 20% of women of childbearing age
may have HBV.
These women constitute a reservoir of perinatal transmission, which is
associated with a very high rate of chronicity (up to 90%)in infants when
HBsAg and HBeAg is positive. Transmission of HBV can be prevented by
vaccination of infants. But despite prophylaxis perinatal transmission of HBV
occurs in a small proportion of infants who receive complete active-passive
immunisation. High maternal viraemia and HbeAg positivity  has been
associated with intrapartum transmission and vaccine breakthrough. Antiviral
therapy during the third trimester of pregnancy in high riskwomen with chronic
HBV infection reduces viral load in the mother  and decrease the risk of
transmission, although data are lacking. Safety data in  pregnancy are most
robust with LAMIVUDINE and TENOFOVIR compared with other  therapies.
Hence effective maternal screening and immunoprophylaxis of neonates
remains the  best method of prevention of  mother to child transmission.
2PREVALENCE AND CLINICAL STUDY OF HEPATITIS B IN
ANTENATAL WOMEN ATTENDING OUT PATIENT CLINIC AT
INSTITUTE OF OBSTETRICS AND GYNAECOLOGY
AIMS AND OBJECTIVES
1.  To study the prevalence of Hepatitis B in antenatal population
2.  To study the course of disease,maternal and perinatal outcome in
Hepatitis B positive     patients.
STUDY CENTRE
Institute of Obstetrics and Gynaecology, Egmore, Chennai – 600 008.
Collaborating Units  Dept of HEPATOLOGY, MMC
DESIGN
Cross sectional study
PERIOD
March 2010- Feb 2011
3REVIEW OF LITERATURE
HEPATITIS B VIRUS
It is the causative agent of what used to be previously called as Serum
Hepatitis or 90 day  Hepatitis. It is the smallest double stranded DNA virus
known to infect man and is the prototype  of the Hepadna virus family which
includes similar viruses infecting ducks(DHBV),ground  squirrels(GSHV) and
woodchucks(WHV).it has the propensity to infect and replicate in the
hepatocytes but appears to have intrinsic cytopathic activity. HBV gains far
more importance  than other forms of hepatitis for its propencity for chronicity
and malignant potential(1,2). It is a  type 1 carcinogen.
HISTORICAL BACKGROUND:
HEPATO-TROPIC means primarily affecting the liver.
HIPPOCRATES in the 8th century suggested the infectious nature of
HBV.
 By 1885, hepatitis was found to be transmittable through blood
transfusion and syringes when epidemics  of jaundice broke out in war victims.
During world war II, between 1939-1945 a series of outbreaks occurred
after vaccination for measles and yellow fever implying further that the virus
was blood-borne.
4In 1947, MACCALLUM classified viral hepatitis into two types: viral
hepatitis A or infectious hepatitis, viral hepatitis B or serum hepatitis.
In 1965, BLUMBERG discovers Australia antigen (HBsAg) in
Aborigines and showed presence  of antigen at high frequency in patients with
leukemia and children of Down syndrome.
In 1968, PRINCE & OKOCHI isolated the Australia antigen in Hepatitis
B patients and from this  information along with discovery of DANE particle in
1970, the first vaccine for Hepatitis B was  produced in 1981 and licensed as
HEPTAVAX
In 1972, HBeAg was discovered
More than a decade later, the nation wide vaccination program on
newborns in Taiwan originally launched in 1984 showed successful results,
with decrease in annual incidence of hepatocellular  carcinoma in children.
STRUCTURE OF HBV
HBV is a complex, 42nm double shelled DNA virus, originally known
as the “DANE particle”.
It has a lipoprotein coat and a nucleocapsid core. The lipoprotein coat is
composed of the hepatitis B surface antigen (HBsAg). The nucleocapsid is
27nm in diameter and has a distinct antigen specificity (HBcAg) along with a
partially double stranded DNA molecule and an  endogenous DNA polymerase
enzyme.
5Electron microscopy of Hepatitis B positive serum reveals 3 morphologically
distinct forms:
1. Small spherical particles with an average diameter of 22nm, these are
antigenic and stimulate the production of surface antibodies. They
outnumber the 42nm virions in the serum. The purified 22nm particles
are used in the preparation of hepatitis B vaccine.
2. Complete 42nm virion (DANE particle), which represents the intact
HBV virion. Of the three morphological forms it is considered to be
infectious. The envelope protein expressed on the outer surface of the
virion and the 22nm spherical  particles is referred to as hepatitis B
surface antigen (HBsAg).
3. The intact 42nm virion contains a 27nm nucleocapsid core particle. The
nucleocapsid core contains two immunologically distinct antigens,
hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg).
6HBV GENOME
Inside the core of the virion is present the viral genome consisting of
HBV DNA and DNA polymerase.The endogenous DNA polymerase have
partially double stranded and partially single  stranded genomes. They rely on a
replicative strategy unique among DNA virus but typical of  retroviruses.
Instead of DNA replication directly from a DNA template, they rely on reverse
transcription effected by the DNA polymerase of minus strand DNA from a
“pregenomic” RNA  intermediate. Then a plus strand DNA is transcribed from
the minus strand DNA template by the  DNA dependant DNA polymerase and
converted in the hepatocyte nucleus into a covalently  closed circular DNA,
with serves as a template  for messenger RNA and Pregenomic RNA.   Viral
proteins are translated by the messenger RNA, and the proteins and genome are
packaged into virions and secreted from the Hepotocyte.
HBV DNA codes for four sets of viral products with a complex,
multiparticle structure. Its compact genomic structure, with overlapping genes,
permits HBV to code for multiple proteins.
HBV achieves its genomic economy by relying on an effiicient  strategy
of  encoding proteins from four overlapping genes: S,C,P & X and four partly
overlapping open reading frames.
7PreS1/PreS2/S gene encoding the Hepatitis B surface protein (HBsAg); the pre
core/ core gene encoding the Hepatitis B e antigen(HBeAg) and Hepatitis B c
protein(HBcAg).the P geneencoding the polymerase proteins and the X gene
encoding the X proteins- HBxAg(3).
The HBe protein is able to cross the placenta, it may make the T cells of
the fetus tolerant of the HBc protein, thus preventing a cytotoxic T cell
response. The HBxAg is capable of transactivating the transcription of both
viral and cellular genes. In the cytoplasm, HBxAg effects calcium release,
which activates signal-transduction pathways that lead to stimulation of HBV
reverse transcription and HBV DNA replication. Such transactivation may
enhance the replication of HBV leading to the clinical association between the
virus and the protein.
HBV GENOTYPES AND MUTANTS
The HBV genome is heterogeneous and can be classified into 8
genotypes : A,B,C,D,E,F,G and H. currently HBV genotype are defined based
on at least 8% divergence across the complete genomic sequence and less than
4% intra-genotypic divergence(4).HBV genotypes are known to  be
geographically segregated (5).  Genotype A is found primarily in North
America, Northern  Europe, India, and Africa. Genotype B and C are common
in Asia; genotype D, in southern  Europe, the Middle East, and India; genotype
E, in West Africa and South Africa; genotype F, in South and Central America;
genotype G, in the United States and Europe (6). Genotype H was  recently
identified in individuals from Central America and California (7). Several
8genotypes  may be associated with the severity of the disease but the
relationshipbetween the genotype and the developing hepatocellular carcinoma
has not been established. In China and Japan, some studies have found more
severe liver disease to be associated with genotype C than compare with
genotype B (8), other studies have found no such association (9,10). There is
some evidence that shows HBeAg seroconversion occurs at a younger age
among individuals infected with genotype B (8,10,11). Genotype D has been
associated with anti-HBe-positive chronic hepatitis B infection  in
theMediterranean region (12).
HBV  has a reported mutation rate of 10 times greater compare with
other DNA viruses. These mutations can occur naturally as well as due to
selective pressure from antiviral therapy. There are five clinically relevant
HBV types: wild-type HBV, precore mutants, core promoter mutants, tyrosine-
methionine-aspartateaspartate (YMDD) mutants induced by lamivudine
treatment, and asparagine to threonine (rtN236T) mutants recently identified in
patients with adefovir treatment.
In a study carried out in the United States, the precore variant of HBV
was rarely found in association with genotype A, but it was found in almost
50% of those with genotype C and in >70% of individuals with genotype D.
Those with precore variant and core promoter mutations had higher HBV DNA
levels in sera than those persons without these mutations. It is observed that
flares in chronic HBV have been associated with increases in concentrations of
precore mutation in proportion to wildtype HBV. Exacerbations have been
thought to subside with time when the genetic heterogeneity disappears and
9patients become exclusively infected with precore HBV. During the treatment
of chronic hepatitis B by lamivudine, drug resistance may develop, which is
mediated by point mutations with the YMDD motif at the catalytic center of
the viral reverse transcriptase. With increase in the mutant viral load, patients
can sustain further liver injury. The YMDD mutant level will decrease after
stopping lamivudine. Viral mutation also occurs in patients on adefovir
treatment during their second year therapy at the rate of 2.5%. The mutation
has been reported as asparagine to threonine mutation (rtN236T), downstream
of the YMDD motif. It is not clear yet if rtN236T mutant can induce further
liver damage.
The hepatitis B virus has 3 distinct antigens:
SURFACE ANTIGEN (HBsAg),CORE ANTIGEN (HBcAg) and E
ANTIGEN (HBeAg)
They stimulate corresponding antibody production in most affected
individuals.
HBsAg exhibits antigenic diversity. It has
? A group specific antigen – a
? Type specific antigens (d-y), (w-r)
Thus there are four major subtypes of HBsAg adw,adr,ayw and ayr. HBsAg is
demonstrable upto 6 weeks and usually disappear 6 – 12 weeks thereafter.
Presence of HBeAg in serum is associated with infectivity in HBV and its
replication. HBeAg correlates with HBV specific DNA   polymerase activity
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and is an indicator of viral load. There is a 85% chance   of   infants becoming
susceptible to HBV if mother is HBeAg+ve. If HBeAg persists for more than 8
weeks recovery is delayed and can go in for chronicity.
HBs ANTIGEN IN LIVER
The virion envelope and the HBs particles are synthesized and
assembled at the membrane of the Endoplasmic reticulum. From the ER the
particles are transported and excreted  by vesicles. However when the largest of
the 3 HBs proteins (LHBs) is overproduced in  comparison with the smaller
HBs protein, filamentous particles are formed that are retained in  the
Endoplasmic reticulum. This may lead to accumulation of HBs protein to the
point that the  Endoplasmic reticulum becomes dilated. In light microscopy,
such large HBs storing hepatocytes  appear opaque like ground glass.
CORE ANTIGEN IN LIVER
The core particles are synthesized and assembled independently from
the HBs proteins. Thereafter they probably attach to patches of HBs protein in
ER membrane. By enclosing the whole core particle the HBs protein would
mediate budding of the virions to the ER lumen. Non  enveloped core particles
of human HBV are found in the nucleus where they are stored. In highly
viremic individuals without high disease activity all hepatocyte may contain
considerable core particles. Non enveloped core particles are not detectable in
the serum. Certain HBV product cell lines secretes not only virions, HBs but
also core particles.
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HBV CARRIER STATE
Persons possessing Hepatitis B surface Antigen in blood for more than 6
months  are called chronic or persistent carriers. Carrier state is lifelong and
may be associated with mild liver damage varying from minor changes in liver
function to chronic active hepatitis, cirrhosis and carcinoma (11). Those with
low levels of HBsAg and absence of HBV and DNA polymerase possess very
low infectivity are termed as simple carriers (11).
LIFE CYCLE OF HEPATITIS B VIRUS:
The hepatitis B virus encompasses six stages beginning from entry into
the host to release of  progeny virions
ATTACHMENT OF VIRUS TO HOST CELL
PENETRATION   IN  TO  CELL
RELEASE OF  VIRAL GENOME
EXPRESSION OF VIRAL GENE PRODUCTS
REPLICATION OF VIRAL GENOME
FORMATION OF VIRIONS & RELEASE
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GLOBAL SCENARIO (13)
Hepatitis B is endemic throughout the world, especially in tropical and
developing countries. Its prevalence varies from country to country and
depends on a complex mix of behavioural, environmental and host factors. In
general it is lowest in countries or areas of high standards of living.
The HBV infection is a global problem, with 66% of all the world’s
population living in areas where there are high levels of infection. More than 2
billion people worldwide have evidence of past or current HBV infection and
350 million are chronic carriers of the virus, which is harboured in the liver,
and causes an estimated 600,000 deaths from cirrhosis of liver and
hepatocellular carcinoma. The virus causes 60-80% of all primary liver cancer.
Between 5% and 10% of adults and upto 90% of infants infected with HBV
become carriers. Among these, 25% in the long term develop liver disease.
Hepatitis B is endemic in China and other parts of Asia . In these regions
8-10% of the adult population are chronically infected. In the middle east and
Indian subcontinent, an estimated 2-5% of general population is chronically
infected. In western Europe and north America less than 1% population is
infected.
Based on the different HBsAg carrier states, countries can be divided
into three categories: high endemicity (> 8%), intermediate endemicity (>2 – 8
%) and low endemicity (< 2%). Countries or regions can be divided into three
epidemiological patterns.
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GEOGRAPHICAL DISTRIBUTION OF HBsAg prevalence
LOW (<2%) INTERMEDIATE
(2-8%)
HIGH (>8%)
 AUSTRALIA  INDIA OTHER PARTS OF
AFRICA
NEW ZEALAND NORTH AFRICA     CHINA & MIDDLE
EAST
NORTH AMERICA OTHER PARTS OF
EUROPE
    PACIFIC ISLANDS
 WESTERN EUROPE JAPAN AND USSR     SOUTH AMERICA
INDIAN SCENARIO (13)
India falls in the intermediate zone of prevalence ranging between 2 to
8%. There are an estimated 43 million estimated HBV carriers in India. 10% of
them are HBeAg positive. The HBV carrier pool has increased from 38 million
to 43 million over a period of one decade.
An analysis of 191 reports from india using ELISA revealed HBsAg
carrier rate to range from 1.10% to 13.1%. the mean of these reports places the
national HBsAg carrier rate at 4.7% out of which HBeAg positivity was
24.43% and anti HBeAg positivity was 39.2%. (10,11)
The HBsAg subtype reports have revealed an interesting pattern. In
North India including Bombay ‘ayw’ subtype seems to predominate (59.1%).
However in South India ‘ad’ aubtype predominates (56.5 – 68.7%). Even with
the ad subtype adw seems to be prevalent in the whole of North India and
Kerala on the other hand ‘adr’ was the major subtype in Tamil Nadu.
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PREVALENCE RATE OF IN GENERAL POPULATION IN
DIFFERENT STATES
UTTAR PRADESH     6.05% HIMACHAL PRADESH    3.26%
KARNATAKA        5% KERALA     1.39%
TAMIL NADU       4.69% DELHI      1.39%
MAHARASHTRA         3% CHANDIGARH      2.4%
RAJASTHAN      1.6% WEST BENGAL      2.29%
HEPATITIS B AND PREGNANCY (13)
The rate of positivity for HBsAg in pregnant women reported in the
Indian literature varies from 0.2% to 7.1% with a weighted average of 2.8%. In
larger studies among carrier females about 5 – 12% have been positive for both
HBsAg and HBeAg.
The state wise prevalence rates of HBV carriers among pregnant
women, Kerala 7.3%, Karnataka 5%, U.P 4.8%, Tamil Nadu 3.9%. a study in
North India showed 3.7% HBV carrier rate among pregnant women and 7.8%
HBeAg positivity in HBsAg carriers. The report in vertical transmission of
hepatitis B in Northern India shows 2.48% positive mothers for HBsAg and
10.3% positivity for babies at birth. In HBeAg positive mothers the babies were
at greatest risk with 70 to 100% infection rate and 17.30% if the mother was
HBsAg alone. If the mother was anti HBe positive the baby had only 12.20%
chance of getting infected.
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EPIDEMIOLOGICAL DETERMINANTS (13)
Agent factors
Of the three morphological forms, only the DANE particle is considered
infectious.
Reservoir of infection
Hepatitis B carrier state act as natural reservoir as there are no animal
carriers for the virus. Risk of chronicity is inversely proportional to the age at
which infection occurs. More than 90% chronicity occurs in infancy in contrast
to 5-10% in adults as it is apparent that infection in infancy and early childhood
is essential for maintenance of HBV infection pool in a population.
Source
A chronic carrier act as a highly infectious source. The level of
infectivity varies, from less than 10 virions per ml to 10 to the power of 8
virions per ml, cases may range from inapparent to symptomatic cases.
In HBV carrier pregnant females, antibody to the ‘e’ antigen does not
indicate a noninfectious state as a significant proportion of such mothers have
high levels of viral  HBV DNA sequences in their serum and are potentially
infectious.
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Infective material
Contaminated blood is the main source of infection, although the virus
has been found in body secretions. 0.0001 ml of contaminated blood when
comes in contact with intact skin act as a potential source of infection.
MODE OF TRANSMISSION
? Sexual transmission occurs in unvaccinated homosexual men and
correlates with multiple partners and unprotected anal sex. Transmission
also occurs after heterosexual contact ( e.g. 18% infection rates for
regular partners of patients with acute hepatitis B) . sex workers are at
high risk.(14-23)
? Other routes are: parenteral ( blood, blood products, drug users sharing
needles and syringes, needle-stick), vertical (infected mother to infant)
and oro-anal sex.(14-26)
? Sporadic infection occurs in people without apparent risk factors, in
institutions for the mentally disabled and also in children in countries of
high endemicity (27,28). Overall, HBV is much more transmissible than
HIV.
RISK FACTORS FOR HBV TRANSMISSION:
? Ethnic and genetic predisposition
? Low socioeconomic status, poor hygiene, sanitation and overcrowding
? Exposure to blood products
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? Percutaneous exposure to infected blood ( health care personnel, drug
abusers, tattooing.)
? Homosexual and heterosexual contact
? Immunocompromised and hemodialysis patients
With reference to age it was reviewed by many authors namely J.
Shanmugam et al., 1981, D Pal et al., 1991 and Kenneth et al., 1995 incidence
is highest among young people between 16-30yrs.
Regarding sex, HBV infection in twice more common in males than
females revealed by D Pal et al., 1991., G.Pellizzer et al., 1994 and probably
because of a more promiscuous nature of the males.
VERTICAL TRANSMISSION OF HBV
Maternal transmission of an infectious agent can be defined as the direct
transfer of the agent from the mother to the child either during pregnancy
transplacentally or at the time of birth during delivery. Mothers with acute
infection in the 1st and  2nd trimester transmit the infection to approximately
10% of their new born, when acute infection occurs in the 3rd trimester 80 to
90% of the new born are infected.
Mechanism of maternal transmission:
1. In utero infection
2. Perinatal transmission
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In utero infection
Intra uterine transmission of viral hepatitis had been suggested by stokes
et al., who first reported neonatal infection. Studies have shown that the infant
does not become infected if hepatitis occurs early in pregnancy. As pregnancy
progresses, the placenta becomes porous, allowing both fetomaternal and
maternal hemorrhages. It appears that this leakage is the major cause of intra
uterine infection with HBV during maternal viraemia whether the infant is
infected in utero or postnatally. If the mother is positive for HBeAg positive the
baby has a 85-90% chance of developing chronic HBV infection.
According to Goldeau et al, transmission of Hepatitis B virus to the
fetus or newborn is more likely to occur when maternal infection occurs during
2 to 3 months preceding delivery. In such cases antigenemia may develop in
40-50% of babies of which only a small percentage of whom will eventually
clear the virus. Placental transfer of Hepatitis B is thought to be rare.
Intra uterine transmission occurs only in 5 to 8% of the infants born to
HBsAg the carriers where as most infection occur  perinatally (Otto et al.,).
Perinatal transmission:
Transmission can take place during,
? Materno fetal transfusion
? Ingestion of maternal blood, blood contaminated liquor, or other
HBeAg containing body fluids during delivery
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Lee et al, demonstrated the presence of HBsAg in 17 out 0f 52 (32.7%)
samples of amniotic fluid extracted at 37 weeks, in 57 out of 58 (95.4%)
samples of gastric fluid aspirated from babies during resuscitation. Thereby
proving the direct evidence for the oral route of infection from carrier mothers
during delivery. Though 95.3% of the babies had the evidence of ingesting
viral antigen, only 70.3% subsequently became HBsAg positive.
Presence of HBsAg in cord blood does not necessarily indicate another
infection as it may represent transient maternally derived antigenemia.
Perinatal infection is much more frequent when the mother carries both the
surface antigen (HBsAg) and ‘e’ antigen (HBeAg) of the virus. In many
instances babies with positive cord blood specimen become negative shortly
after birth. Persistent antigenemia is affected by maternal antibody titre and
antigenemia in siblings. Antigenemia that developed in the first six months of
life suggests transmission at birth. Infants who develop chronic HBsAg
carriage due to perinatal infection are sources of continuous exposure to
siblings and the rest of population.
The relative contribution of hematogenous infection to neonatal
acquisition and the contact with maternal blood and vaginal secretions during
delivery has not been completely elucidated. For that reason the use of
caesarean delivery for the prevention of neonatal infection is controversial.
Transplacental leakage of blood or micro transfusion during labour rather than
exposure in the birth canal appears to be a major mode of transmission. Thus
risk of transmission is significantly lower when elective caesarean section is
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done before onset of labour  whereas LSCS after onset of labour does not lower
transmission.
Infants born to HBsAg positive mothers need not be isolated at birth.
However the mothers secretions should be considered potentially infectious
and managed with universal precautions. Risk of transmission is greatest if the
mother has a history of transmission to her previous children. There are no
teratogenic syndromes associated with HBsAg in pregnancy and outcome of
pregnancies complicated by HBsAg are no different than those of other women
in the same population. Boxall in 1974 detected the presence of HBsAg in
breast milk. It is possible that infection may be transmitted postnatally either by
virus present in milk or infectious serum from the cracked nipple.
INCUBATION PERIOD
30 to 180 days. Lower doses of the virus result often in longer
incubation period. The average incubation period is about 75 days (13).
STAGES OF HBV INFECTION
An individual can develop hepatitis B infection that is acute and achieve
complete immune clearance of virus yielding lifelong immunity; however, an
alternate fate of the host is the development of chronic hepatitis B. there are 3
stages of HBV infection based on viral host interaction,
1. Immune tolerant phase
2. Immune clearance phase
3. Inactive carrier phase with or without reactivation
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After acute infection of HBV, some patients may remain HBeAg
positive with high levels of HBV DNA levels, little or no symptoms, normal
ALT levels and minimal histological activity in the liver, this phenomenon is
known as the immune tolerance phase. This phase is typical of infection in
children and young adults. It usually lasts for 2-4 weeks, but can last for years
in those who acquired the infection in the perinatal period (28). Individuals in
this group are highly contagious and can transmit HBV easily. When the
tolerogenic effect is lost during the immune tolerant phase, immune mediated
lysis of infected hepatocytes become active and patients enter the second stage
defined as immune clearance phase, the HBV DNA level decreases and ALT
level increases. The duration of clearance lasts from months to years. This is
followed by carrier stage, in which seroconversion of HBeAg to HBeAb
occurs, HBV DNA becomes non-detectable or at low level and ALT is usually
normal, reflecting very low or no replication of HBV and mild or no hepatic
injury. The inactive carrier stage may last for even years or life time. Patients in
this stage can have spontaneous resolution of hepatitis B and develops HBsAb,
but a portion of them may undergo spontaneous or immunosuppression-
induced reactivation of chronic hepatitis, features elevated ALT, high level of
DNA, moderate to severe liver histological activity, and with or without
HBeAg seroconversion.
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CLINICAL SPECTRUM OF HBV INFECTION
ACUTE HEPATITIS B
Majority of HBV infection in children are asymptomatic versus those in
adults, about 30 to 50% develop acute icteric hepatitis. Those who recover
should acquire lifelong immunity. However, a subset of patients will be
chronically infected and very few patients (0.1 – 0.5%) can develop fulminant
hepatitis. In primary infection, HBsAg becomes detectable after 4 to 10 weeks
of incubation period, followed by antibodies against the core antigen (HBcAb)
in IgM form during the early period (7). Viremia is well established by the time
HBsAg is detected (usually from 10^9 to 10^10 per milliliter) (29). Circulating
HbeAg becomes detectable in most cases. When liver injury occurs in acute
infection, ALT levels do not increase until after viral infection is well
established, reflecting the time required to generate the T-cell-mediated
immune response that triggers liver injury. Once this response has commenced,
viral titres in blood and liver begins to drop. With clearance of the infection,
HBsAg and HBeAg disappear, and free HBsAb becomes detectable. Presence
of HBsAg for greater than 6 months implies progression to chronic infection.
When persistent infection establishes, the serology markers like HBeAg,
HBeAb and HBsAb can be positive or negative except HBsAg and HBcAb
(IgM form) remain positive.
HBeAg positive chronic hepatitis B
 Age at the time of infection is a strong determinant of chronicity, the
earlier the acquisition of infection, the higher probability of developing chronic
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infection. Levels of viremia in chronic infection are generally significantly
lower than during acute infection. In adult acquired disease, the early phase of
infection often is accompanied by significant disease activity with elevated
ALT levels versus those who acquired the infection perinatally usually have
normal ALT levels. Many patients with perinatal infection enter the
immunoactive phase and develop HBeAg positive chronic hepatitis with
elevated ALT levels only after 10-30 years of infection (30). A key event in
natural history of progression is HBeAg seroconversion to HBeAb with marked
reduction of HBV replication followed by gradual histological improvement
(31). In studies, the observed clearance of HBeAg is about 50% and 70%
within 5 and 10 years of diagnosis respectively (31). Most studies found the
mean annual rate of spontaneous seroconversion is 8% to 15% in individuals
with active liver disease, but those with normal ALT levels tend to have
smaller annual conversion rate of 2% to 5%.
HBeAg negative chronic hepatitis B
 These individuals have a naturally occurring mutant form of HBV that
does not produce HBeAg, due to a mutation in the precore or core promoter
region. Most frequent precore mutation is a G-A change at nucleotide 1896
(G1896A) which creates a stop codon and results in loss of HBeAg synthesis;
the most common core promoter mutation involves a 2 nucleotide substitution
at nucleotide 1762 and 1764 (32). HBeAg-negative carriers are a
heterogeneous group and most of them have low viral HBV DNA levels,
relatively normal levels of alanine aminotransferase, and a fair prognosis.
However, in Asia, Middle East, Mediterranean basin and southern Europe,
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about 15% to 20% of these carriers have elevated alanine aminotransferase and
viral DNA (33). HBeAg-negative chronic hepatitis B (precore mutant) emerges
as the predominant species during the course of typical HBV infection with
wild-type virus and is selected during the immune clearance phase (HBeAg
seroconversion) (34). There are 2 main patterns of disease activity in this
subgroup of patients: 30%-40% of patients experience persistent elevated ALT
levels (3-4 folds) and the remaining 60%-70% patients can have erratic ALT
patterns with frequent flares. Sustained spontaneous remission is rare (6% to
15%) in these individuals, and spontaneous HBsAg clearance is only about
0.5% per year (35); hence, long-term prognosis is poorer among HBeAg-
negative individuals than compare with their counterparts who are HBeAg-
positive.
Inactive HBsAg carrier state:
 Inactive HBsAg carrier state is diagnosed by HBeAg negativity with
anti-HBe positivity, undetectable or low HBV DNA level, repeatedly normal
ALT, and normal or minimal histological evidence of damage (36). The
prognosis of the inactive carrier is generally good and well supported by long-
term follow-up studies (37,38,39). An estimated 20% to 30% of HBsAg
carriers may develop reactivation of hepatitis B with elevation of biochemical
levels, high serum DNA level with or without sero-reversion to HBeAg.
Recurrent episodes of reactivation or sustained reactivation can occur and
contribute to progressive liver disease and decompensation. Frequently, HBV
reactivation is usually asymptomatic, but it may mimic acute viral hepatitis. On
the other hand, some carriers eventually become HBsAg negative and develop
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HBsAb. It is reported that the incidence of delayed HBsAg clearance is close to
1% to 2% per year in Western countries, but only 0.05% to 0.8% per year in
endemic areas where infection was often acquired during childhood.
Reactivations of HBV replication in patients who receive immunosuppressive
therapy or cytotoxic chemotherapy have been reported in the range of 20% to
50% in chronic carriers (40,41); from experience, the combined use of
corticosteroid in chemotherapies significantly increases the risk of reactivation
(40). However, these flares in the immunosuppressed individuals rarely result
in significant hepatic decompensation.
Long-term Sequelae of Chronic Hepatitis B
Cirrhosis
Following the diagnosis of chronic hepatitis B, the survivals in these
patients are estimated to be 100% at 5 years. However, cirrhosis and hepatoma
are two major long-term complications of chronic HBV infection that
significantly increases morbidity and mortality. In patients without cirrhosis, if
untreated, the incidence of liver related death is low and ranges from 0 to 1.06
per 100 person years. The mortality rate at 5 years is 16% for those with
compensated cirrhosis and is 65% to 86% for decompensated cirrhosis (42,43).
In untreated individuals with predominantly HBeAg positive chronic hepatitis
B, the incidence of cirrhosis ranges from 2 to 5.4 per 100 person years with a 5-
year cumulative incidence of cirrhosis of 8% to 20% (45). A higher rate of
cirrhosis has been reported in HBeAg-negative as compared to HBeAg-positive
patients. Also, older age and persistent viral replication are predictors for
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development of cirrhosis as well as mortality. Genotype C is associated with a
higher risk of cirrhosis than genotype B based on studies in Asian patients( 44).
The presence of any other independent hepatotoxic factors such as alcohol
ingestion, HCV co-infection can contribute to progression to cirrhosis. Once
cirrhosis is established, individuals can decompensate over time.
Hepatocellular Carcinoma
The development of hepatocellular carcinoma (HCC) and liver failure
are main cause of death from chronic hepatitis B. It is estimated that over
500,000 people die each year from the consequence of HBV infection (45).
HCC incidence is three to six times higher in males than in females, suggesting
a tumorigenic effect of androgens (47). Several studies have indicated that
older age(>45 years) is an important determinant of HCC, this may either
reflect a longer duration of viral infection and liver disease or agemay be an
independent risk factor. Having a first degree relative with HCC, the presence
of cirrhosis, and reversion activity are all thought to contribute to HCC
development (47,48,49). Chronically infected subjects have a 100 times
increased risk of hepatocellular carcinoma compare with non-carriers . A recent
study suggested positive HBsAg increased one’s risk of developing HCC by 10
folds, and with positive HBeAg, HCC is significantly increased by 60 folds.
Moreover, a detectable HBV DNA level yields a 4 fold increase risk of HCC
(50). The additional use of alcohol, consumption of aflatoxin in diet and
coinfection with HCV or HDV are independent factors for HCC in HBV
infected patients. Unlike hepatitis C, development of HCC in hepatitis B
patients does not require preceding cirrhosis. Hence, it is advocated that all
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HBV infected patients, regardless of cirrhosis status, should get screening for
HCC every 6 months with alpha-fetoprotein (AFP) and ultrasonogram
abdomen.
VIRAL ANTIGENS AND HOST ANTIBODY RESPONSES:
Serological testing for the diagnosis of Hepatitis B virus infection
involves measurement of a panel of distinct HBV-specific antigens and host
antibodies that react to these antigens.(51,52,53). The interpretation of these
tests can be complicated, and multiple possibilities exist based on the overall
panel of responses. In general, the panel of responses can determine whether a
patient is susceptible to infection, immune as a result of vaccination or resolved
infection and acute or chronically infected.
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SEROLOGICAL RESPONSE TO ACUTE HBV INFECTION:
The incubation period typically consists of 8 to 12 weeks (51). During
acute infection, the appearance of virological markers and host antibody
response develop in a typical pattern. The first serological marker to appear is
hepatitis B surface antigen (HBsAg), which can initially be detected in the
serum from 1 to 12 weeks (30 to 60 days) after infection. Shortly thereafter,
hepatitis B e antigen (HBeAg) generally becomes evident (54,55) . although
serum assays will show presence of HBV DNA prior to the appearance of
HBsAg or HBeAg, with HBV levels often exceeding 1000000000 virions/ml,
this test is not generally performed for the diagnosis of acute HBv infection
(56). About that time the clinical symptoms develop, antibody to hepatitis B
core antigen appears (anti HBc), primarily detectable as IgM class (IgM anti
HBc). In addition, with the onset of clinical symptoms, patients will have
increases in serum hepatic aminotransferase levels that reflect hepatic injury.
The degree of hepatic injury generally correlates directly with the vigor of the
immune response (53). Although IgM anti HBc typically decline to
undetectable levels within 6 months, IgG class persists indefinetly as a marker
of past HBV infection.
SEROLOGICAL RESPONSE WITH RESOLVED HBV INFECTION
Following acute HBV infection, the evolution of the pattern of
serological markers depends on the outcome of host immune response. The
likelihood of resolving HBV infection correlates with their age and the strength
of the initial immune response to HBV (52,53). Following an acute infection,
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approximately 90% of adults will resolve the HBV infection whereas 30 to
40% of young children go in for chronicity. The weak immune response
generated by young children acutely infected with HBV generally corresponds
with minimal bleeding of the HBV infected hepatocytes; for this reason,
clinical symptoms suggestive of  acute HBV infection are frequently absent in
this patient population (56). For those patients who resolve their infection,
HBsAg disappears at about 3 to 6 months, often just prior to the detection of
antibodies to hepatitis B surface antigen (anti HBs). The presence of anti-HBs
following acute infection generally indicates recovery and protective immunity
against re-infection. In addition, patients with resolution of infection have
disappearance of HBeAg and development of antibodies to hepatitis B e
antigen (anti HBe). Patients with resolved infection have persistence of anti
HBs for life, but about 4 to 6 months after appearance of anti HBc
predominantly consists of  IgG. Some patients with self limited infection,
however may still have HBV DNA in blood; whether the HBV DNA is part of
intact virions is unknown (56,57).
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SEROLOGICAL RESULT WITH CHRONIC HBV INFECTION:
Patients who develop persistant HBV infection have a serological
response in the acute phase of HBV infection that is similar to patients who
subsequently resolve the HBV infection. With persistent HBV infection,
HBsAg and antiHBc (IgG antibodies) generally persist for life and HBV DNA
can usually be detected by nucleic acid amplification methods. The presence of
HBsAg for longer than 6 months after acute infection indicates chronic
infection. The detection of HBsAg and the absence IgM anti HBc in a single
serum specimen also generally indicates chronic HBV infection. Although
most persons with chronic HBV infections are without symptoms, they are at
risk for subsequently developing chronic hepatitis, cirrhosis and carcinoma
(52). The continued presence of HBeAg generally reflects higher HBV DNA
levels and greater infectiousness. Some patients with chronic HBV infection
may have resolution of their HBeAg along with appearance of anti HBe and
this usually correlates with low HBV levels and relatively normal levels of
hepatic aminotransferase levels. Newer more sensitive PCR assays have shown
that greater than 70% of persons who develop anti-HBe have persistent HBV
DNA, typically in the range of 1000 to 100,000 mol/ml (56,59). In addition,
some patients with chronic HBV infection have absent HBeAg, increased
aminotransferase levels and relatively high HBV DNA levels; these findings
generally occur in association with pre-core or core mutation. These mutations
prevent or diminish HBeAg formation by an otherwise normally replicating
HBV (56,60).
32
PREVENTION:
Three main strategies are available for the prevention of HBV infection:
(1)  behavior modification to prevent disease transmission
(2)  passive immunoprophylaxis
 (3)  active immunization.
Behavior Modification
Hepatitis B transmission can be reduced by avoiding unprotected
penetrative anal and vaginal sex and oro-anal contact, or by using condoms if
the partner is HBsAg positive or their status is unknown (61). [IIa, B].
Improved screening measures of blood products have reduced the risk of
transfusion-associated hepatitis. Behavior modification is thought be more
beneficial in developed countries than in developing countries, where neonates
and children in early childhood are at the greatest risk of acquiring infection. In
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these group, immunoprophylaxis, both passive and active, will be more
effective.
Passive Immunoprophylaxis:
Hepatitis B Immune Globulin (HBIG) is a sterile solution of ready-made
antibodies against hepatitis B. HBIG is prepared from human blood from
selected donors who already have a high level of antibodies to hepatitis B and
used in passive immunoprophylaxis.
 Passive immunoprophylaxis is used in four situations
(1)  newborns of mothers infected with hepatitis B
(2) after needlestick exposure
(3)  after sexual exposure
(4)  after liver transplantation.
Immunoprophylaxis is recommended for all infants born to HBsAg
positive mothers. Current dosing recommendations are 0.13ml/kg HBIG
immediately after delivery or within 12 hours after birth in combination with
recombinant vaccine. The combination results in a higher-than-90% level of
protection against perinatal acquisition of HBV (62). Between 3.7% to 9.9% of
infants still acquire HBV infection perinatally from HBVinfection mothers,
despite immunoprophylaxis (22-27). Failure of passive and active
immunoprophyxis in this setting may be the result of in utero transmission of
HBV infection, perinatal transmission related to a high inoculum, and/or the
presence of surface gene escape mutants.  However, the preventive effect of
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HBIG administration before delivery needs to be confirmed by more study in
the future.
Hepatitis B immune globulin remains a central component of
prophylaxis in HBV-infected patients undergoing liver transplantation. HBIG
monotherapy given at a high dosage can prevent recurrence in 65% to 80% of
patients. Because the cost of long-term prophylaxis with high-dose HBIG is
extremely high and combination therapy using HBIG with a nucleoside analog
is more uniformly effective, the current protocol is combination HBIG with a
nucleoside analog after liver transplantation. Thesecombination protocols have
reduced the rate of virologic breakthrough to 10% or less (63).
Active Immunization
?  The World Health Organisation recommends universal HBV
vaccination.
?  If universal vaccination is not pursued it should be offered to non-
immune patients in most of the high risk groups (16,17,64,65).[Ia, A]
The main exception is people born in countries of high endemicity but
not at continuing risk who are being screened primarily to detect chronic
HBV carriage (66,67). [IIa, B]
?  HIV positive patients show a reduced response rate to the vaccine
(approximately 40%) and initial responders can become anti-HBs-
negative within a year (69,70). [IIa, B].
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?  There are three possible vaccination schedules for both the monovalent
and the combined hepatitis A+B vaccines: 0 ,1, 6 months, 0, 1, 2 and 12
months (‘rapid course’) or 0, 1, 3 weeks, and 12 months (‘ultra-rapid
course’) (61-65). [IIa, B] Non- or poor responders usually respond to
further doses (up to three injections normal or double dose), ideally
given as a repeat Course (63,64) [IIa, B]. Some newer vaccines are more
immunogenic including Fendrix ™, which has a novel adjuvant and the
pre-S-antigen-containing vaccines. Currently Fendrix is only licensed
for use in patients with renal insufficiency and pre-S vaccines have not
been launched commercially (58-62).
?  If the primary course of vaccination is incomplete, the missing doses of
vaccine needed to complete the course can be given up to four years
later without the need to restart the full course [III, B]
?  Some patients test anti-HBc positive but negative for anti-HBs and
HBsAg. This could be due to either past infection or may be a false-
positive test. A single hepatitis B vaccine dose will induce anti-HBs if
there has been past natural HBV exposure (amnestic response, measured
4 weeks after single dose of HBV vaccine). If anti-HBs is still negative
after a single booster, regard as non-infectious and give a full course of
HBV vaccine [III.B]
?  Recent evidence suggests that immuno-competent adults and children
who have responded to a primary course of HBV vaccine (>10 IU/l) do
not require booster doses for at least fifteen years [III, B].
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However, immuno-compromised patients, such as those with HIV or
renal failure, require booster doses of vaccine when the anti-HBs level falls
below 10 IU/l [IIa, B].
Management of HBsAg-positive patients
General
?  Patients should be advised to avoid unprotected sexual intercourse,
including oro-anal contact until they have become non-infectious or
their partners have been successfully vaccinated  . [IIa,B]
?  Patients should be given a detailed explanation of their condition with
particular emphasis on the long-term implications for the health of
themselves and their partner(s), routes of transmission of infection and
advised not to donate blood  [III, B]
?  Hepatitis B is a notifiable disease in many European countries (71).
?  If not performed already, screen for other sexually transmitted diseases
in cases thought to have been sexually acquired or if otherwise
appropriate (29,33)[III,B]
?  Other tests such as liver biopsy or assessment of liver fibrosis (for
assessment of chronic disease) should be performed by specialists in this
field (51)[IV, C]
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Indications for therapy of Chronic Infection
?  Treatment should normally be given in collaboration with a hepatologist
or physician experienced in the management of chronic viral hepatitis
[IV, C]. The decision to treat depends on pattern of disease, HBV-DNA
level, and presence or absence of significant necro-inflammation and
hepatic fibrosis. HBV-DNA thresholds of 2x10^4, 2x10^3 and 2x10^3
IU/ml, are often used for HBeAg+ve, chronic hepatitis, HBeAg –ve
chronic hepatitis and cirrhosis respectively, for initiating therapy (72)
?  Patients should be considered for therapy with lamivudine, adefovir,
tenofovir, telbivudine, entecavir (or combinations of nucleos(t)ide
analogues) or pegylated interferon [Ib, A]. Additional treatments that
may soon be licensed in HBV monoinfection include emtricitabine
(FTC) [Ib,A], clevudine [IIa,B] and valtorcitabine [III,C] (79-81).
Treatment responders have long-termbenefits in terms of reduced liver
damage and decreased risk of liver cancer (72-81)
?  All patients should have an HIV test prior to starting HBV therapy
because of the different treatment strategies required and the significant
risk of antiretroviral- resistant HIV developing if lamivudine, tenofovir
or entecavir are used as monotherapy [Ib,A] (72,73, 82-84).
?  Lamivudine, emtricitabine and tenofovir will suppress hepatitis B viral
replication during therapy of HIV and may delay liver damage if given
as part of combination antiretroviral therapy. [Ib, A] (83-85).
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?  Lamivudine and emtricitabine should only be given to HIV+ patients in
combination with tenofovir as part of HAART because of the high rate
of resistance that occurs to these drugs if given as the only HBV-active
agent [Ib,A] (83-85) .Entecavir should not be used in HIV+ patients
without adequately suppressed HIV as it causes the M184V
(lamivudine/emtricitabine) resistant mutation (82) and there is some
evidence that telbivudine may also have HIV activity (86) [III,B]
?  Adefovir can be used alone in HIV+ patients (87) [IIa,B]
?  Specific therapy may not be indicated, based on the HBV-DNA viral
load, unless de-compensated liver disease has ensued, but all HBsAg+ve
patients should receive long-term follow-up due to the risk of liver
cancer . Hepatitis A vaccination should be offered if non-immune, due
to the worse prognosis of dual infection (88) [III,B]
Special situations
Pregnancy and Breastfeeding
?  Vertical transmission (mother to infant) of infection occurs in 65-90% of
pregnancies where the mother is HBeAg positive and in about ten
percent of HBsAg positive, HBeAg negative mothers. Most (>90%) of
infected infants become chronic carriers (89).
?  Infants born to HBsAg positive mothers are vaccinated from birth,
sometimes in combination with Hepatitis B specific Immunoglobulin
(HBIG) 200 i.u. intramuscularly (89) [IIa,B]. This reduces vertical
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transmission by approximately ninety percent. There is some evidence
that lamivudine may further reduce vertical transmission if given to
women with a high HBV-DNA viral load in the third trimester (90) [Ib,
A]. However, if HBSIg is not available, vaccination alone prevents
vertical transmission in 66-100% (89) [IIa, B]. Infants should be tested
for hepatitis B (HBsAg and anti-HBs) 4-6 weeks after the final dose of
vaccine [IV, C].
?  Infected mothers should continue to breast feed as there is no additional
risk of transmission.
Management of partners and other contacts
?  Partner notification should be performed and documented and the
outcome documented at subsequent follow-up. Contact tracing to
include any sexual contact (penetrative vaginal or anal sex or oro/anal
sex) or needle sharing partners during the period in which the index case
is thought to have been infectious (91) [IIa, A]. The infectious period is
from two weeks before the onset of jaundice until the patient becomes
HBsAg negative. In cases of chronic infection trace contacts as far back
as any episode of jaundice or to the time when the infection is thought to
have been acquired although this may be impractical for periods of
longer than two or three years [IV, C]. Arrange screening for hepatitis B
of children who have been born to infectious women if the child was not
vaccinated at birth [IV, C].
40
?  If available, HBSIg 500 i.u. intramuscularly may be administered to a
nonimmune contact after a single unprotected sexual exposure or
parenteral exposure or needle-stick injury if the donor is known to be
infectious. Passive immunization should be given as early as possible as
it is of no use after more than seven days (92)[IIa,A]
?  An accelerated course of recombinant vaccine should be offered to those
given HBSIg plus all sexual and household contacts (at 0 ,1, 2,12
months or 0, 1, 3 weeks, 12 months) (83-87) [IIa,B]
?  Avoid sexual contact, especially unprotected penetrative sex, until
vaccination has been successful (anti-HBs titres >10i.u./l.) [IIa, B].
Condoms will reduce the rate of transmission of hepatitis B if the patient
and partner continue to have sex [III, B].
Follow-up (81-92)
?  Acute infection: regular Liver function tests (1-4 weekly) until normal.
In view of the possibility of chronic infection, serum HBsAg should be
repeated after six months even if the LFT is normal  [III, B].
?  Chronic infection: If untreated, patients should be regularly reviewed at
intervals of one year or less, ideally by a physician with expertise in this
disease [IV, C]
?  Immunity after recovery from infection is lifelong in all but a very tiny
minority [III, B].
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MATERIALS & METHODS
STUDY POPULATION
Antenatal women attending out patient clinic at IOG
SAMPLE SIZE
All antenatal women attending out patient clinic within the study period.
INCLUSION  CRITERIA
All antenatal women attending out patient clinic are included in the
study
INVESTIGATIONS
Initial investigations: HbsAg and anti Hbc
Patients who are reactive to either of the above tests are subjected to the
following tests
? Complete hemogram
? Liver function test
? Renal function test
? HBV DNA for viral load
? HBeAg
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? Ultrasound Abdomen and pelvis
? Family screening
DATA COLLECTED
Socio demographic data, clinical data, laboratory data
DATA ANALYSIS
All the data collected were entered in MS EXCEL sheet and statistical
analysis done by student t test (test of probability) and chi square test; p value
below 0.01 taken as highly significant, < 0.05 as significant and >0.05 as non
significant.
PRINCIPLE OF THE PROCEDURE
HBsAg:
Detected by using Hepanostika Test kit (ELISA) method. Hepanostika
uniform II is a ELISA based on a one step ‘sandwich’ principle.
Anti HBc antibody
Wellcozyme anti HBc is an enzyme labeled immunoassay (EIA) kit for
detection of antibody to hepatitis B core antigen.
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HBeAg/Anti HBe
Wellcozyme HBeAg/Anti HBe is also an enzyme immunoassay to
detect corresponding antigen and antibody
HBV DNA
Real time PCR technique. HBV DNA quantified using COBAS TAQ
MAN kit.
44
OBSERVATION & RESULTS
SOCIO-DEMOGRAPHIC DETAILS:
Of the 2730 women screened, 1228 (45%) were from urban sector and
1502 (55%) were from sub-urban and rural sectors. A majority of women
belonged to low socio-economic class i.e. class 4 (1062; 38%) and class 5
(1583; 60%), only 3 women belonged to middle class according to revised
Kuppuswamy’s scale.
2
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HBsAg PREVALENCE RATE:
Out of the 2730 women screened, 160 tested positive for hepatitis B
surface antigen. Seroprevalence accounts to about 5.86%.
94.14
5.86
HBsAg
neg
HBsAg
positive
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AGE WISE DISTRIBUTION:
The highest prevalence of HBsAg was observed in the age group 21-25
yrs (82/1082; 7.58%) followed by 26-30 yrs (45/864; 5.20%). The difference in
HBsAg prevalence rate in different age groups was statistically significant with
p < 0.01.
AGE  GROUP TOTAL SEROPOSITIVES SERONEGATIVES
15 – 20 YRS 382 18 (4.7%) 364
21 – 25 YRS 1082 82 (7.5%) 1000
26 – 30 YRS 873 45 (5.1%) 828
31 – 35 YRS 302 11 (3.6%) 180
> 35 YRS 91 3 (3.2%0 88
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PARITY DISTRIBUTION
The prevalence rate increased with increase in parity. It was highest
among multigravida (98/1375; 7.12%), followed by second and primi gravid
with a prevalence of 4.73% and 4.6% respectively. The prevalence rate in
different group was statistically significant with p < 0.05.
GRAVIDITY TOTAL SERO
POSITIVE
SERO
NEGATIVE
PRIMIGRAVIDA 407 19 (4.6%) 388
SECONDGRAVIDA 948 43(4.7%) 905
MULTIGRAVIDA 1375 98(7.1%) 1277
48
TRIMESTER DISTRIBUTION
The seroprevalence in different trimesters were almost similar and
statistically insignificant with p >0.05.
TRIMESTER TOTAL SEROPOSITIVES
SERO
NEGATIVES
FIRST 573 27 (4.7%) 546
SECOND 764 45 (5.8%) 719
THIRD 1665 88 (5.3%) 1577
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RISK FACTORS FOR HBV INFECTION AMONG HBsAg POSITIVE
WOMEN:
Previous history of jaundice was observed to be high i.e. 45/160(
28.12%). 36 women had history of prior surgery, of which 27 of them had
underwent obstetrical procedures including Dilatation & Curettage,
Hysterotomy and Lower segment caesarean section. 9 patients underwent
gastrointestinal, cardiothoracic and orthopaedic surgeries. 28 out of 160 gave
history of blood transfusion within 5 yrs. History of tattooing observed in 14
HBsAg positive women.
Regarding information on HBsAg positivity among husbands of
seropositive women,17/160 were positive. Among them one was a health care
worker. One women was a nurse in the seropositive group.
28.12
23.1317.5
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VIRAL MARKERS AND TRIMESTER DISTRIBUTION
40/160 HBsAg positive women tested positive for HBeAg antigen. Of
these 18 had acute infection{IgM anti HBc positive} and 22 were chronic. 58
HBeAg negative patients were tested for HBV DNA and anti HBe antibody. 26
were positive for HBV DNA and anti HBe, 32 were positive for anti HBe
alone. Only HBsAg positivity alone was observed in 62 women.
VIRAL
MARKERS
I
TRIMESTER
II
TRIMESTER
III
TRIMESTER
HBsAG 27  (16.8%) 45 (28.1%) 88 (55%)
IgM ANTI-HBc 6  (23.6%) 2 (7.6%) 18 (69.2%)
HBeAg 8 (20%) 8  (20%) 24 (60%)
HBV DNA 11 (25%) 7  (15.9%) 26  (59%)
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VERTICAL TRANSMISSION
              Transmission among babies was tested by cord blood HBsAg
positivity at birth.  Of the 18 acutely infected patients , 10 babies were
affected.14 babies were affected among the chronic infection group. Mothers
who were positive for HBV DNA and anti HBe antibody transmitted their
infection to 16 babies. Only 1 baby was affected in the only anti HBe positive
group. 3 babies were affected in isolated HBsAg positivity. The difference in
transmission among babies in the various serological groups was statistically
significant  with a p value < 0.01.
SEROLOGY PATIENTS
SERO
POSITIVE
BABIES
SERO
NEGATIVE
BABIES
ACUTE HEPATITIS (HBsAg,
ANTI HBc IgM,HBeAG, HBV
DNA POSITIVE)
18 10(53%) 8
CHRONIC HEPATITIS
(HBsAg, HBeAg POSITIVE) 22 14(63.6%) 8
HBsAg, HBV DNA, ANTI HBe
POSITIVE
HBeAg NEGATIVE
26 16(61.4%) 10
HBsAg, ANTI HBe POSITIVE
HBeAg, HBV DNA
NEGATIVE
32 1(3.12%) 31
               HBsAg POSITIVE 62 3(4.8%) 59
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MODE OF DELIVERY
      123 out of the 160 positive women delivered normally. 37 underwent lower
segment cesarian section all for obstetrical indications.
123
37
VAGINAL
LSCS
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PERINATAL OUTCOME
BABY WEIGHT
TOTAL
NUMBER
PRETERM TERM
< 2 KGS 18 11 7
2 TO 3 KGS 128 22 106
>3 KGS 14 -
14
1 among the term babies whose mother was HBeAg and HBV DNA
positive in the third trimester was an IUD. Other causes for intrauterine term
IUD like gestational diabetes, pre eclampsia, ante partum hemorrhage[abrutio
placenta], nuchal cord and congenital anomalies were ruled out .
There were 56 neonatal admissions . Of them 29 were pre term , 11 were
low birth weight term babies, 16 were birth aspyxiants.
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Comparative of Seroprevalence rates of HBs Ag and HBeAg
Among pregnant women in different populations.
Author,
Year and
reference
Population
studied
Number of
persons
screened
HBsAg +ve
(%)
HBeAg +Ve
(% of HBsAg
positive)
Mohammed
et.al. 2008
Saudi Arabia 1.60
Bertolini
et.al. 2006
Brazil 3,188 1.50
Khalil et.al.
2005
Saudi Arabia 2.44 0.15
Panda
et.al.1991
India 8,431 2.6 12.5
Gill et.al.
1995
India 2,000 5.0 12.0
Biswas
et.al.1989
India 1,000 2.3 48
Mittal et.al.  India 850 6.3 18
Manisha
et.al. 2008
Allahabad,
India
4,000 0.9 57
Present
Study, 2010
Chennai,
Tamilnadu,
India
2,730 5.86 25
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DISCUSSION
          In this study the sero prevalence of HBsAg among pregnant women was
found to be  5.86%. sero epidemiological studies of different populations show
variations and  differences. These differences can be attributed to various
factors like type of population  studied, geographical region, genetic factors
and socio economic conditions. The HBsAg positivity in antenatal pregnant
women in India ranges from 1 to 12.3% with a mean of 4.22%. Similar study
conducted by manisha et al in 2008 at Allahabad reported 0.9 % prevalence.
Other studies conducted in india between 1987 – 2000. Nayak et al ( 3.7% ),
panda et al ( 2.6%), gill et al (5.0%) , biswas et al (2.3% ) and mittal et al
observed 6.3% prevalence rates.
A significant difference and increase in prevalence rate was observed
with increasing age among the seropositive group as reported in many other
Indian and foreign studies, except for the  Allahabad study (manisha et al in
2008) where a slight non significant decline was observed with increasing age
group. Also a higher and statistically significant frequency of HBsAg positivity
was observed in multigravida.
According to Centres for Disease Control guidelines, every pregnant
women should be tested for HBsAg during each pregnancy. Our results show
that the HBsAg tests have been done more in the third trimester. This is due to
lack of awareness among pregnant women.
In our study, even though history of jaundice was observed in high
percentage among the seropositive women, such icteric episodes could not be
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taken as a significant risk factor as the cause of the icteric episode cannot be
ascertained. However there were a small percentage of seropositive patients
without any identifiable risk  factors. Also a significant percentage among the
seronegative group had one or two risk factors.
HBeAg positivity rate among HBsAg positive antenatal women have
shown geographical  variations  in different parts of india as reported by
Shenoy et al. HBeAg positivity in our study  {25%} was 50 % less study
conducted by Manisha et al at Allahabad.
Mothers who were affected in the 3rd trimester transmitted infection to
the babies moré than the mothers infected in 1st and 2nd trimester. Similar
results were found in other  studies. A significant association between e antigen
positivity and HBV DNA and transmission  of infection to babies was observed
in our study . This once again proves that the combination of e antigen and
HBV DNA is a more sensitive indicator of vertical transmission.
Two women had high titres of HBV DNA (> 100000) and presence of
HBeAg, detected in the third trimester, both of them were started on
LAMIVUDINE 100 mg twice daily and advised to continue 6 weeks
postpartum.
Transmission rates and significance depending on the mode of delivery
could not be ascertained because all patients who were screened did not deliver
in our institution, hence baby follow up was practically difficult for all patients.
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CONCLUSION
? The seroprevalence rate for Hepatitis B in antenatal women was found
to be 5.86% in our study. This places our part of the country in the
intermediate endemicity zone.
? Statistically significant difference was observed in age and parity
distribution, whereas no such difference was observed in trimester
distribution due to lack of awareness about Hepatitis B among pregnant
women.
? HBeAg and HBV DNA positivity in antenatal mothers increases the risk
of vertical transmission. This has been proved in our study which
showed significantly higher rates of transmission and adverse perinatal
outcome in third trimester infections.
? As evident from our study  vertical transmission and health care
providers are at risk of contracting Hepatitis B infection, hence routine
screening for all antenatal women and routine immunization for all
health care workers is recommended
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MASTER CHART – 1
SOCIO DEMOGRAPHIC DETAILS
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
254 SUMATHY 3 1 2 5 2 2
261 THYBUNISHA 2 1 2 5 1 1
219 KALAIRANI 2 1 2 5 2 1
385 LAKSHMI 4 1 2 5 3 1
396 YAMINI 2 1 3 4 2 2
487 SHARMILA 2 1 2 5 1 3
512 KANNIAMMAL 3 1 2 5 3 3
528 INDUMALAR 2 1 3 4 1 2
580 RADHA 1 1 3 4 1 2
603 PREMA 3 1 2 5 4 3
634 SUMATHY 2 1 2 5 2 1
637 GRACY 5 1 3 4 1 2
646 JAYANTHI 2 1 3 5 2 2
656 MARIAMMAL 2 1 2 5 1 2
670 BANUPRIYA 2 1 3 5 1 3
677 HEMAVATHY 2 1 3 5 1 2
695 VEERALAKSHMI 3 1 2 5 2 3
721 KAVITHA 2 1 3 5 2 3
736 REKHA 2 1 2 5 2 2
771 SUMATHY 4 4 3 4 2 2
836 BHARANI DEVI 2 1 3 4 1 3
860 JENNIFER 3 1 2 5 2 1
816 JAYANTHI 2 1 2 5 3 2
937 GEETHA 4 1 2 5 2 1
954 PADMAVATHY 3 1 2 5 2 2
981 RAJESHWARI 2 1 2 5 2 3
1000 BAGYALAKSHMI 2 3 3 4 1 2
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
1006 SHANTHY 3 1 3 4 1 2
1008 KALAIYARASI 1 1 3 4 1 1
1110 THILAGAVATHY 3 1 2 5 3 2
1182 SHANTHY 2 1 3 4 1 3
1185 MEENATCHI 1 1 3 4 1 1
1194 PRIYA 2 1 2 5 2 2
1208 VASANTHI 5 1 2 5 3 3
1215 CHITRA 2 1 2 5 1 3
1255 GEETHA 2 1 3 4 1 3
1265 JEGADEESWARI 2 1 3 4 2 3
1282 SHAJITHA 1 1 2 5 1 2
1289 MAHESWARI 2 1 3 4 2 3
1306 MENAKA 2 1 2 5 1 1
1319 TAMILSELVI 2 1 2 5 2 3
1322 ASIA BEGUM 2 1 2 5 1 3
1341 GEETHA 2 1 2 5 1 3
1343 LATHA 2 1 3 4 2 2
1388 SARANYA 3 1 3 4 2 1
1429 SUGANYA 4 1 3 4 2 3
1430 RAJALAKSHMI 2 1 3 4 2 3
1431 SUDHA 1 1 2 5 1 2
1437 BHOOPATHY 2 1 2 5 2 3
1450 SANGEETHA 1 1 4 4 3 3
1453 AMUDHA 2 1 3 4 1 3
1457 KALAIVANI 3 1 3 4 1 3
1465 FATHIMA 2 1 3 4 1 1
1473 RANGAMMAL 2 1 2 5 3 3
1482 SANDIYA 2 1 2 5 3 3
1497 SARASWATHI 1 1 2 5 2 3
1520 NATHIYA 1 1 3 4 1 3
1526 REVATHI 2 1 3 5 1 3
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
1538 MEENATCHI 2 1 2 5 1 1
1540 CHITRA 1 1 3 5 1 2
1542 MAHALAKSHMI 2 1 2 5 1 1
1543 DHANALAKSHMI 4 1 3 5 2 3
1544 GOVINDAMMAL 2 1 2 5 2 3
1558 FATHIMA 2 1 2 5 3 3
1568 PADMAVATHY 2 1 3 4 1 3
1581 SHOBANA 3 1 2 5 1 2
1592 ILAKIYA 2 1 2 5 1 3
1600 SUDHA 3 1 2 5 4 3
1612 RUTH BABY 3 1 2 5 1 3
1613 SASIKALA 2 1 2 5 1 2
1627 ASSERIEN 1 1 2 5 1 3
1651 SANDRA 1 1 2 5 3 2
1713 NIRMALA 2 1 3 4 2 3
1757 SARASWATHI 3 1 3 4 2 2
1768 RESHMA 2 1 3 4 4 3
1777 DHANALAKSHMI 2 1 3 4 2 3
1790 SHAKILA 3 1 3 4 5 2
1886 PUSHPALATHA 3 1 2 5 2 1
1949 LAKSHMI 2 1 3 4 2 3
2032 MEGALA 3 1 2 5 2 3
2037 SANGEETHA 2 1 3 4 2 3
2039 AMLORPAVAMARY 4 1 3 4 1 2
2071 BANUMATHY 3 1 3 4 5 2
2075 FATHIMA 3 1 3 4 3 1
2085 VIJAYALAKSHMI 3 1 3 4 1 2
2109 JAYANTHI 3 1 2 5 2 3
2115 GOMATHI 2 1 2 5 3 3
2139 KAVITHA 3 1 3 4 3 2
2152 NARMADHA 2 1 3 4 3 2
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
2191 NAGAMMAL 1 1 2 5 1 2
2210 MANJULA 3 1 2 5 2 2
2264 SUNDARI 2 1 3 4 1 2
2290 RENUKA 4 3 3 3 2 2
2331 SASIKALA 2 1 2 5 1 3
2334 BALAKAVITHA 3 1 3 4 2 1
2398 DEEPALAKSHMI 2 1 3 4 2 1
2401 AMULMANI 5 3 2 4 2 3
2405 JAYA 3 1 3 4 2 3
2414 SUGUNA 3 1 3 4 2 1
2436 RANI 3 1 2 5 3 3
2439 SANGEETHA 2 1 3 4 2 1
2479 SARANYA 2 1 2 5 3 1
2483 SUJATHA 2 1 3 4 1 3
2489 RAMEEZABAI 2 1 2 5 2 1
2490 UMAPRIYA 4 1 3 4 1 3
2510 KUMARI 1 1 2 5 2 3
2514 SUBEDHA 3 1 3 4 2 3
2519 JAYANTHI 3 1 3 4 3 3
2536 KAVITHA 2 1 3 4 2 3
2546 SATHIYA 2 1 3 5 2 3
2564 KODEESWARI 3 1 3 4 1 2
2603 MARAGATHAM 3 1 3 4 2 3
114 LAKSHMI 1 1 3 4 1 1
115 PUSHPALATHA 2 1 3 5 1 1
116 NAZIRA BANU 2 1 2 5 2 2
117 SARITHA 2 1 3 4 3 1
118 RADHIKA 3 1 2 5 1 2
119 VIJAYALAKSHMI 4 1 3 4 4 1
120 JAMUNA 1 1 3 4 1 2
122 KALAVATHI 2 1 2 5 3 3
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
123 SUBHA 2 1 2 5 1 1
124 SHABHANA 3 1 3 4 2 1
125 KODEESWARI 2 1 2 5 2 1
130 MARAGATHAM 3 1 3 4 2 3
137 DEVIKA 1 1 2 5 1 3
139 MANJULA 2 1 2 5 1 3
4 VIJAYALAKSHMI 4 1 2 5 2 2
9 USHA 2 1 2 5 1 1
11 MALLIGA 2 1 3 4 2 3
25 MALATHY 3 1 2 5 2 2
34 SHEELA 2 1 2 5 1 3
35 NAVANEETHAM 2 1 2 5 4 2
47 MALINI 2 1 2 5 1 2
54 JOTHI 3 1 2 5 2 3
63 KRISHNAVENI 2 1 2 5 1 3
70 EZHILARASI 2 1 3 4 1 3
82 SENTHAMARAI 3 1 3 4 2 3
98 REENA 3 1 2 5 1 3
103 SUGUNA 2 1 2 5 1 3
104 SUMATHY 1 1 2 5 1 2
106 SUMATHY 3 1 3 4 2 3
110 SHYLAJA 2 1 2 5 1 3
2607 CHITRA 2 1 2 5 1 2
2615 KANCHANA 2 1 2 5 1 3
2616 PANDISELVI 1 1 2 5 1 3
2618 BACKIALAKSHMI 2 1 2 5 1 3
2620 JAYANTHI 2 1 2 5 1 3
2622 VIMALA 2 1 3 4 1 3
2628 ASHIYA BEGUM 3 1 2 5 1 3
2632 DHANALAKSHMI 3 1 2 5 1 3
2633 MUTHULAKSHMI 3 1 3 4 2 3
H.
NO
NAME AGE OCC S.OCC SE
CLASS
GRAVIDITY TRIME-
STER
2636 RAJESHWARI 2 1 2 5 1 3
2641 KALAIARASI 1 1 2 5 1 3
2643 SANDYA 3 1 2 5 1 3
2650 KAVITHA 4 1 2 5 1 3
2652 SHANTHI 2 1 2 5 2 3
2674 SIVAGAMI 3 1 2 5 2 3
2680 VIMALA 3 1 2 5 4 3
2684 SANGEETHA 2 1 2 5 1 3
2691 SUNDARI 2 1 2 5 1 3
MASTER CHART – 2
PAST HISTORY
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
SUMATHY 2 2 1 0 2 1 2 2
THYBUNISHA 2 2 2 0 2 1 1 1
KALAIRANI 2 2 2 0 2 1 2 2
LAKSHMI 2 2 2 0 2 1 2 2
YAMINI 2 2 2 0 2 1 2 2
SHARMILA 2 2 2 0 2 1 2 2
KANNIAMMAL 2 1 2 0 1 1 2 2
INDUMALAR 2 2 2 0 2 1 2 2
RADHA 2 2 2 0 2 1 2 2
PREMA 1 2 2 0 2 1 1 1
SUMATHY 2 2 1 0 2 1 2 2
GRACY 2 2 1 0 2 1 2 2
JAYANTHI 2 2 1 0 2 1 2 2
MARIAMMAL 2 2 1 0 2 1 2 2
BANUPRIYA 2 2 2 0 2 1 2 2
HEMAVATHY 2 2 1 0 2 1 2 2
VEERALAKSHMI 2 2 2 0 2 1 1 1
KAVITHA 1 2 1 0 2 1 2 2
REKHA 2 2 2 1 2 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
SUMATHY 2 2 2 0 2 1 2 2
BHARANI DEVI 1 2 1 0 2 1 1 1
JENNIFER 2 2 2 0 1 1 2 2
JAYANTHI 2 2 2 0 2 1 2 2
GEETHA 2 2 2 1 2 1 2 2
PADMAVATHY 2 2 2 0 2 1 2 2
RAJESHWARI 2 2 1 0 2 1 2 2
BAGYALAKSHMI 2 2 1 2 2 1 1 2
SHANTHY 2 2 2 0 2 1 2 2
KALAIYARASI 2 2 2 0 2 1 2 2
THILAGAVATHY 2 2 2 0 2 1 2 2
SHANTHY 2 2 1 0 2 1 1 1
MEENATCHI 2 2 2 0 2 1 1 1
PRIYA 2 2 1 0 2 1 2 2
VASANTHI 2 2 2 0 2 1 2 2
CHITRA 2 1 2 0 2 1 2 2
GEETHA 1 2 2 0 2 1 2 2
JEGADEESWARI 2 2 2 1 2 1 2 2
SHAJITHA 2 1 2 0 2 1 2 2
MAHESWARI 1 2 2 0 1 1 2 2
MENAKA 2 2 2 0 2 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
TAMILSELVI 2 2 2 0 2 1 2 2
ASIA BEGUM 2 1 2 0 2 1 2 2
GEETHA 1 2 2 0 2 1 2 2
LATHA 2 2 2 1 2 1 2 2
SARANYA 1 2 2 0 2 1 2 2
SUGANYA 2 2 2 1 2 1 2 2
RAJALAKSHMI 2 2 1 1 2 1 2 2
SUDHA 2 2 2 0 2 1 2 2
BHOOPATHY 2 2 1 0 2 1 1 2
SANGEETHA 2 2 2 0 2 1 2 2
AMUDHA 2 2 2 0 2 1 2 2
KALAIVANI 2 2 2 2 1 1 2 2
FATHIMA 2 2 2 0 2 1 2 2
RANGAMMAL 2 2 2 1 1 1 1 2
SANDIYA 2 2 1 0 2 1 1 2
SARASWATHI 2 1 2 0 2 1 2 2
NATHIYA 2 2 1 0 2 1 2 2
REVATHI 2 2 2 0 2 1 2 2
MEENATCHI 2 1 2 0 2 1 2 2
CHITRA 1 2 2 0 2 1 1 1
MAHALAKSHMI 2 2 2 2 1 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
DHANALAKSHMI 2 1 2 1 1 1 2 2
GOVINDAMMAL 2 2 2 0 2 1 2 2
FATHIMA 2 2 2 0 2 1 2 2
PADMAVATHY 2 2 2 0 2 1 2 2
SHOBANA 2 2 2 1 1 1 2 2
ILAKIYA 2 2 1 0 2 1 1 2
SUDHA 2 2 2 0 1 1 2 2
RUTH BABY 1 2 1 0 2 1 2 2
SASIKALA 2 2 2 0 2 1 2 2
ASSERIEN 2 2 2 0 2 1 1 1
SANDRA 2 2 1 2 1 1 2 2
NIRMALA 2 2 2 0 1 1 2 2
SARASWATHI 2 2 2 0 2 1 2 2
RESHMA 2 2 2 1 2 1 2 2
DHANALAKSHMI 2 2 2 0 2 1 2 2
SHAKILA 2 2 2 0 2 1 2 2
PUSHPALATHA 2 2 2 1 1 1 2 2
LAKSHMI 2 2 1 1 2 1 1 1
MEGALA 2 2 2 1 2 1 2 2
SANGEETHA 2 2 2 0 2 1 2 2
AMLORPAVAMARY 1 2 2 0 2 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
BANUMATHY 2 2 1 1 1 1 2 2
FATHIMA 2 2 2 2 1 1 2 2
VIJAYALAKSHMI 2 2 1 0 2 1 2 2
JAYANTHI 2 2 1 1 2 1 1 2
GOMATHI 2 1 1 0 2 1 2 2
KAVITHA 2 2 1 1 2 1 1 2
NARMADHA 2 2 2 1 1 1 2 2
NAGAMMAL 2 2 2 0 2 1 2 2
MANJULA 2 2 2 1 2 1 2 2
SUNDARI 2 2 2 0 2 1 2 2
RENUKA 1 2 2 1 2 1 2 2
SASIKALA 2 2 1 0 2 1 1 2
BALAKAVITHA 2 1 1 0 2 1 1 1
DEEPALAKSHMI 1 2 2 0 2 1 2 2
AMULMANI 2 2 1 0 2 1 2 2
JAYA 1 2 1 0 2 1 2 2
SUGUNA 2 1 1 0 2 1 2 2
RANI 2 2 2 0 2 1 2 2
SANGEETHA 2 2 1 0 2 1 1 1
SARANYA 2 2 2 1 1 1 2 2
SUJATHA 2 2 1 0 2 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
RAMEEZABAI 2 2 1 1 2 1 2 2
UMAPRIYA 2 2 1 0 1 1 2 2
KUMARI 2 2 2 0 2 1 2 2
SUBEDHA 2 2 2 1 2 1 2 2
JAYANTHI 2 2 2 0 2 1 2 2
KAVITHA 2 2 1 0 2 1 2 2
SATHIYA 1 2 1 0 2 1 2 2
KODEESWARI 2 2 1 0 2 1 1 1
MARAGATHAM 2 2 1 1 1 1 2 2
LAKSHMI 2 2 2 2 1 1 2 2
PUSHPALATHA 2 2 2 0 1 1 2 2
NAZIRA BANU 2 1 2 0 2 1 1 2
SARITHA 2 2 2 1 1 1 2 2
RADHIKA 2 2 2 2 1 1 2 2
VIJAYALAKSHMI 2 2 2 1 1 1 2 2
JAMUNA 2 2 2 0 2 1 2 2
KALAVATHI 2 1 2 0 2 1 2 2
SUBHA 2 2 2 2 1 1 2 2
SHABHANA 2 2 2 0 2 1 2 2
KODEESWARI 2 1 2 1 2 1 2 2
MARAGATHAM 2 2 2 0 2 1 1 1
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
DEVIKA 2 2 2 0 2 1 2 2
MANJULA 2 2 1 0 1 1 2 2
VIJAYALAKSHMI 2 2 1 0 1 1 1 2
USHA 2 2 2 0 2 1 2 2
MALLIGA 2 2 2 0 2 1 2 1
MALATHY 2 2 2 0 2 1 2 1
SHEELA 2 2 1 0 2 1 2 1
NAVANEETHAM 2 2 2 0 2 1 1 2
MALINI 2 2 1 0 1 1 2 1
JOTHI 2 2 2 0 2 1 2 1
KRISHNAVENI 1 2 1 1 2 1 1 1
EZHILARASI 2 2 2 0 2 1 1 1
SENTHAMARAI 2 2 2 0 2 1 2 1
REENA 2 2 2 0 2 1 2 1
SUGUNA 2 2 1 0 2 1 2 1
SUMATHY 2 2 2 0 2 1 1 1
SUMATHY 2 2 2 0 2 1 1 2
SHYLAJA 2 1 2 0 2 1 2 2
CHITRA 2 2 1 0 2 1 2 2
KANCHANA 1 2 2 0 2 1 2 2
PANDISELVI 1 1 2 0 2 1 2 2
NAME SPOUSE TATOOING JAUNDICE SURGERY TRANSFUSION HBsAG ANTI HBC IgM HBc
BACKIALAKSHMI 1 2 2 0 2 1 2 2
JAYANTHI 2 2 2 0 2 1 2 2
VIMALA 2 2 2 0 2 1 2 2
ASHIYA BEGUM 2 2 2 0 2 1 2 2
DHANALAKSHMI 2 2 2 0 2 1 2 2
MUTHULAKSHMI 2 2 2 0 2 1 1 1
RAJESHWARI 2 2 2 0 2 1 2 2
KALAIARASI 2 2 2 0 2 1 2 2
SANDYA 2 2 2 0 2 1 1 2
KAVITHA 2 2 2 2 1 1 2 2
SHANTHI 2 2 2 0 2 1 1 1
SIVAGAMI 2 2 2 0 2 1 2 2
VIMALA 2 2 2 0 2 1 2 2
SANGEETHA 2 2 2 0 2 1 2 2
SUNDARI 2 2 1 0 2 1 2 2
MASTER CHART -3
VIRAL MARKERS & BABY DETAILS
NAME HBeAg ANTI
Hbe
HBV
DNA
DELI-
VERY
BABY BABY
WEIGHT
SUMATHY 2 2 N 1 2 2
THYBUNISHA 1 2 2341 2 2 2
KALAIRANI 2 2 N 1 2 2
LAKSHMI 2 1 11236 1 1 2
YAMINI 2 1 N 1 2 2
SHARMILA 1 2 N 1 1 2
KANNIAMMAL 2 2 N 1 2 2
INDUMALAR 2 1 N 1 2 2
RADHA 2 2 N 1 1 2
PREMA 1 2 112362 1 2 2
SUMATHY 2 2 N 1 2 2
GRACY 2 1 N 1 2 2
JAYANTHI 2 2 N 1 2 2
MARIAMMAL 2 1 N 1 2 2
BANUPRIYA 2 2 N 1 2 2
HEMAVATHY 2 2 N 1 2 1
VEERALAKSHMI 1 2 111123 1 1 2
KAVITHA 1 2 5625 1 2 2
REKHA 2 1 N 2 2 2
SUMATHY 2 1 13872 1 1 3
BHARANI DEVI 1 2 11657 1 1 2
JENNIFER 2 2 N 1 2 2
JAYANTHI 2 2 N 1 2 2
GEETHA 1 2 N 2 1 2
PADMAVATHY 2 2 N 1 2 1
NAME HBeAg ANTIHbe
HBV
DNA
DELI-
VERY BABY
BABY
WEIGHT
RAJESHWARI 2 1 N 1 2 2
BAGYALAKSHMI 2 2 N 1 2 1
SHANTHY 2 1 5712 2 1 1
KALAIYARASI 2 2 N 1 2 2
THILAGAVATHY 2 2 N 1 2 2
SHANTHY 1 2 5437 2 1 2
MEENATCHI 1 2 N 2 2 2
PRIYA 2 1 N 1 2 3
VASANTHI 1 1 N 2 2 2
CHITRA 2 1 3249 1 1 2
GEETHA 1 2 N 1 2 1
JEGADEESWARI 2 2 N 2 2 2
SHAJITHA 2 2 N 2 2 2
MAHESWARI 2 1 N 2 2 2
MENAKA 2 2 N 1 2 2
TAMILSELVI 2 1 N 1 2 2
ASIA BEGUM 1 2 N 1 1 2
GEETHA 1 2 N 1 2 2
LATHA 2 2 N 1 2 2
SARANYA 2 2 N 1 2 2
SUGANYA 2 1 6243 1 1 3
RAJALAKSHMI 2 1 N 1 2 1
SUDHA 2 2 N 2 2 1
BHOOPATHY 2 2 N 1 2 2
SANGEETHA 2 2 N 1 2 2
AMUDHA 2 1 761 1 2 2
KALAIVANI 2 1 N 1 2 2
FATHIMA 2 2 N 1 1 2
NAME HBeAg ANTIHbe
HBV
DNA
DELI-
VERY BABY
BABY
WEIGHT
RANGAMMAL 1 2 N 1 1 2
SANDIYA 2 1 N 1 2 2
SARASWATHI 2 2 N 1 2 2
NATHIYA 2 1 2130 1 2 2
REVATHI 2 2 N 2 2 2
MEENATCHI 2 2 N 1 2 2
CHITRA 1 2 N 1 2 2
MAHALAKSHMI 2 1 N 1 2 2
DHANALAKSHMI 2 2 N 2 2 1
GOVINDAMMAL 1 2 N 1 2 2
FATHIMA 1 2 N 1 2 2
PADMAVATHY 2 2 N 1 2 2
SHOBANA 2 1 7914 1 1 2
ILAKIYA 2 1 N 1 2 3
SUDHA 2 2 N 1 2 2
RUTH BABY 1 2 N 1 2 2
SASIKALA 2 1 N 1 2 2
ASSERIEN 1 2 11352 1 1 2
SANDRA 2 1 1472 1 2 2
NIRMALA 2 2 N 1 2 3
SARASWATHI 1 2 N 1 1 2
RESHMA 2 1 N 2 2 2
DHANALAKSHMI 2 1 N 1 2 2
SHAKILA 2 1 7635 1 1 1
PUSHPALATHA 1 2 N 2 2 2
LAKSHMI 1 2 N 2 1 1
MEGALA 2 2 N 2 2 2
SANGEETHA 2 1 N 2 2 2
NAME HBeAg ANTIHbe
HBV
DNA
DELI-
VERY BABY
BABY
WEIGHT
AMLORPAVAMARY 2 2 N 1 2 1
BANUMATHY 2 1 2081 2 1 2
FATHIMA 2 2 N 1 2 2
VIJAYALAKSHMI 1 2 N 2 2 2
JAYANTHI 2 2 N 2 2 2
GOMATHI 2 2 N 1 2 2
KAVITHA 2 1 N 2 2 3
NARMADHA 1 2 N 2 1 2
NAGAMMAL 2 2 N 1 2 2
MANJULA 2 1 21721 2 1 2
SUNDARI 2 1 N 1 2 2
RENUKA 2 1 N 2 2 2
SASIKALA 2 2 N 1 2 2
BALAKAVITHA 1 2 1165 1 2 3
DEEPALAKSHMI 2 2 N 1 2 2
AMULMANI 2 1 11231 1 1 2
JAYA 1 2 N 1 2 2
SUGUNA 2 1 N 1 2 2
RANI 2 2 N 1 2 2
SANGEETHA 1 2 N 1 2 2
SARANYA 2 1 N 2 2 1
SUJATHA 2 2 N 1 2 2
RAMEEZABAI 2 1 11162 2 1 2
UMAPRIYA 2 2 N 1 2 2
KUMARI 2 1 N 1 2 3
SUBEDHA 1 2 N 2 1 2
JAYANTHI 2 2 N 2 2 2
KAVITHA 2 2 N 1 2 2
NAME HBeAg ANTIHbe
HBV
DNA
DELI-
VERY BABY
BABY
WEIGHT
SATHIYA 2 1 N 1 2 2
KODEESWARI 1 2 N 1 1 2
MARAGATHAM 2 2 N 2 2 2
LAKSHMI 2 2 N 1 2 1
PUSHPALATHA 1 2 N 1 2 2
NAZIRA BANU 2 2 N 1 2 2
SARITHA 2 2 N 1 2 2
RADHIKA 2 1 2628 1 1 2
VIJAYALAKSHMI 2 1 N 1 2 3
JAMUNA 2 2 N 1 2 3
KALAVATHI 1 2 N 1 2 1
SUBHA 2 2 N 1 2 3
SHABHANA 2 1 1921 1 2 2
KODEESWARI 2 1 N 1 2 2
MARAGATHAM 1 2 N 2 IUD 1
DEVIKA 2 2 N 1 2 2
MANJULA 2 1 1378 1 2 2
VIJAYALAKSHMI 2 2 3.18 1 2 2
USHA 1 2 N 1 1 2
MALLIGA 2 1 N 1 2 2
MALATHY 2 2 N 2 2 2
SHEELA 2 1 31821 1 1 2
NAVANEETHAM 2 2 N 2 2 2
MALINI 1 2 N 1 2 2
JOTHI 2 2 N 1 2 1
KRISHNAVENI 1 2 1000 1 1 2
EZHILARASI 1 2 1123 1 2 2
SENTHAMARAI 2 2 N 2 2 2
NAME HBeAg ANTIHbe
HBV
DNA
DELI-
VERY BABY
BABY
WEIGHT
REENA 2 1 1323 1 2 3
SUGUNA 2 1 N 1 2 1
SUMATHY 1 2 1032 1 1 2
SUMATHY 2 2 N 1 2 2
SHYLAJA 2 1 N 1 2 2
CHITRA 2 2 N 1 2 2
KANCHANA 1 2 N 1 1 2
PANDISELVI 2 2 N 2 2 2
BACKIALAKSHMI 2 1 812 1 2 2
JAYANTHI 2 2 N 1 2 2
VIMALA 2 1 1192 1 2 2
ASHIYA BEGUM 2 1 N 1 2 2
DHANALAKSHMI 2 1 N 1 2 3
MUTHULAKSHMI 1 2 N 1 2 2
RAJESHWARI 2 1 4694 1 1 2
KALAIARASI 2 1 5328 2 1 2
SANDYA 2 1 N 1 2 2
KAVITHA 2 1 122 1 2 2
SHANTHI 1 2 N 1 1 2
SIVAGAMI 2 1 N 2 1 2
VIMALA 2 1 122 1 2 3
SANGEETHA 2 1 1421 1 1 2
SUNDARI 2 2 N 1 2 1
KEY TO MASTER CHART
AGE:
15-20 YRS : 1
21-25 YRS : 2
26-30 YRS : 3
31-35 YRS : 4
>35 YRS    : 5
OCCUPATION:
Unemployed           : 1
Labourer                 : 2
Self-employed        : 3
Health care worker : 4
SOCIO-ECONOMIC CLASS : REVISED KUPPUSWAMY SCALE
GRAVIDITY:
Primigravida : 1
II gravida       : 2
Multigravida : 3, 4 and 5
TRIMESTER:
First     : 1
Second : 2
Third    : 3
RISK FACTORS:
Presence of risk factor : 1
Absence : 2
SURGERY:
No surgery : 0
Obstetric procedure : 1
Other surgery  : 2
SEROLOGY;
Positive :1
Negative : 2
DELIVERY:
Vaginal delivery : 1
LSCS : 2
BABY WEIGHT:
< 2 kgs : 1
2-3 kgs : 2
>3 kgs  : 3
ABBREVIATIONS
HAV Hepatitis A virus
HBV Hepatitis B virus
HCV Hepatitis C virus
HDV Hepatitis D virus
HEV Hepatitis E virus
HIV Human Immunodeficiency Virus
HCC Hepato Cellular Carcinoma
DNA Deoxyribonucleic acid
RNA Ribonucleic acid
HBsAg Hepatitis b surface antigen
ANTI HBc Antibody against core antigen ( total & IgM)
HBeAg                              Hepatitis B e antigen
ANTI HBe                        Antibody against e antigen
HBV DNA                        Hepatitis B Deoxyribonucleic acid
SGOT                               Alanine aminotransferase
SGPT Aspartate  aminotransferase
SAP Serum Alkaline phosphatase
LFT Liver function tests
ELISA Enzyme Linked Immunosorbent Assay
RFT Renal function tests
PCR Polymerase Chain Reaction
